ArticleJournal for immunotherapy of cancer2018

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Rikke B Holmgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.